Published on 13th April 2023
NEW YORK (April 13, 2023) – The Worldcom Public Relations Group, the leading global partnership of independent public relations firms, released today The 2023 Worldcom Digital Health Monitor. The Report shows that the world’s leading pharmaceutical companies continue to spurn the opportunity to connect via social media at a local level. However, the use of apps almost doubled.
In Worldcom’s 2023 issue of the Digital Health Monitor, the third time the analysis has been run, Worldcom Healthcare selected 25 pharmaceutical companies based on their global reputation, their size and geographic presence. The report analyzes and ranks their online presence globally, and in 25 countries, across 11 digital channels, including apps, blogs, corporate and local company websites, Facebook, Instagram, LinkedIn, Pinterest, Snapchat, TikTok, Twitter, and YouTube.
Receive Worldcom Insights
Keep up to date with our latest news and analysis by subscribing to our regular newsletter.
Top five overall rankings
Serge Beckers, chairman of Worldcom Healthcare, said: “While the use of social media continues to increase, pharmaceutical firms continue to miss out on local engagement. App use has increased but visual platforms like YouTube and TikTok and mainstream social media platforms like Facebook, remain underutilized at a local level.
The pandemic and other crises have raised expectations that companies should be more purpose-driven. Pharma companies are missing the opportunity to convey, at a local level, how they satisfy heightened consumer expectations around topics such as DEI and ESG. While there is strict regulation on commercial topics, the human issues relating to purpose present a significant opportunity for pharma companies to build emotional equity with consumers and influencers.”
Key findings from the Worldcom Digital Health Monitor
All the companies have a global website, not every country has its own website. The average number of local sites is 20, out of a possible 25 countries.
While all but two of the companies have a ‘global blog’, local blogs remain hard to find. Sanofi makes most use of the opportunities blogs offer, scoring 40%. Lonza does not use the potential of this medium at all.
The use of Apps continues to grow. All companies in the study have ‘international apps’. On average, the companies have around six apps available in the 25 countries. Adding the ‘international apps’ increases the average number to around 11. Pfizer, Janssen, Novartis, Novo Nordisk, AbbVie and Takeda Pharmaceutical have at least 11 local apps available.
Social media channels
Facebook – All pharmaceutical companies in the study but two (Astellas and Merck) have international Facebook accounts. However, overall, Facebook is only being used to 10% of its potential, mainly due to the lack of country-specific accounts and content.
Twitter – International Twitter accounts have been set up by all companies but Astellas. Twenty-one out of 25 countries score lower than 20% for ‘efficient use of Twitter’.
LinkedIn – Global LinkedIn accounts are present in all 25 companies, but only two companies (Novartis and Roche Pharmaceuticals) achieve a LinkedIn efficiency over 20%. This relatively low overall score is mainly due to the fact that country-specific pages and local language content is not common.
YouTube – Local YouTube accounts are available in only a handful of countries, and the same is true for other channels with visual focus, such as Instagram.
TikTok – TikTok isn’t used at all. This highlights that these pharmaceutical companies may be missing an opportunity to engage and build trust with younger generations on platforms they use.
Worldcom Healthcare’s top five (of 10) recommendations to improve ROI from online communications.
Read previous Worldcom Digital Health Monitor Reports.
The study covers 25 countries: Australia, Belgium, Brazil, Bulgaria, Canada, China, Czech Republic, France, Germany, Hungary, Ireland, Italy, Japan, Kenya, Malaysia, Netherlands, Spain, Sweden, Switzerland, Thailand, Turkey, United Arab Emirates, United Kingdom, Vietnam and the United States.
The 25 pharmaceutical companies included in the study are:
AbbVie, Amgen, Astellas Pharma, AstraZeneca, Bayer (Pharmaceuticals Division), Biogen, Bristol Myers Squibb, CSL, including CSL Behring, Eisai, Eli Lilly, Gilead Sciences, GlaxoSmithKline (GSK), Janssen, Lonza, Merck & Co., Merck KGaA, (life sciences plus healthcare revenue), Novartis, Novo Nordisk, Organon, Pfizer, Roche Pharmaceuticals, Sanofi, Takeda Pharmaceutical, Teva Pharmaceutical Industries, UCB.
About The Worldcom Public Relations Group
The Worldcom Public Relations Group is the world’s leading partnership of independently owned public relations firms, with 143 offices employing some 2,000 staff in 115 cities across six continents. In total, Worldcom partners reported combined revenue of US$300+ million last year from 3,034 clients. Established in 1988, the group was formed so that the strongest, most capable independent firms could deliver immediate impact and sustained value through the intelligent use of communications – wherever in the world a client needs support. Partners serve national, international, and multinational clients, while retaining the flexibility and client-service focus inherent in independent agencies. Through Worldcom, clients have on-demand access to in-depth communications expertise from professionals who understand the language, culture, and customs of the geographic areas in which they operate.
Connect with The Worldcom Public Relations Group on Facebook and LinkedIn
Learn more about Worldcom at www.worldcomgroup.com or contact Todd Lynch at 1-800-955-9675 or [email protected].
Chairman of Worldcom Public Relations Group Healthcare Practice Group
See original press release here: Pharmaceutical Multinationals Continue To Spurn The Opportunity To Connect Via Social Media At A Local Level | Business Wire
15 Dec 2021The Power of Patient Storytelling
This insight post is a summary of the original blog post published…
14 Jan 20212021 PR & Sector Trends Predictions from Worldcom Experts - Part 4
In the fourth part of a four-part series, our consultants take a…
18 Nov 2020A New Way to Recruit for Clinical Trials in the COVID-19 Era
This insight post is a summary of the original blog post authored…